Skip to main content
    A

    AngioDynamics Inc (ANGO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $11.87
    -0.11 (-0.96%)

    Market Cap: $499.19M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AngioDynamics Inc (ANGO) Earnings: Report Dates and Results

    Updated Oct 8, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    AngioDynamics (ANGO) is expected to report earnings on Jan 4, 2027. In the quarter ended Aug 31, 2026, AngioDynamics reported EPS of -$0.04, above the -$0.10 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +37.57%
    Streak
    3 Q

    Upcoming Estimates

    Reports Jan 4, 2027 (est.)Period ending Nov 30, 2026
    EPS Consensus-$0.07
    Range-$0.11 - -$0.02
    3 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-22.2%
    60d ago-$0.08+12.0%
    30d ago-$0.08+12.0%
    7d ago-$0.08+12.0%
    Current-$0.07
    Revenue Consensus
    $84.27M
    Range$83.00M - $85.40M
    4 analysts
    Reports Mar 31, 2027 (est.)Period ending Feb 28, 2027
    EPS Consensus-$0.09
    Range-$0.10 - -$0.07
    3 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-50.0%
    60d ago-$0.06-50.0%
    30d ago-$0.06-50.0%
    7d ago-$0.06-50.0%
    Current-$0.09
    Revenue Consensus
    $83.25M
    Range$81.90M - $84.00M
    4 analysts

    Next Report

    ANGO has an expected report date of Jan 4, 2027.

    ANGO Earnings Call

    The latest ANGO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, ANGO beat 25, missed 10 and matched 4. Revenue for the quarter ended Aug 31, 2026 was $80.92M, up 6.9% from $75.71M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Aug 31, 2026-$0.04-$0.10-$0.13 - -$0.10+60.00%BeatN/A30 up, 2 downOct 8, 2026$80.92M
    May 31, 2026-$0.07-$0.11-$0.11 - -$0.07+36.36%BeatN/A31 up, 1 downJul 14, 2026$86.61M
    Feb 28, 2026$0.02-$0.11-$0.12 - -$0.10+118.18%Beat-33.3%30 up, 2 downApr 2, 2026$78.42M
    Nov 30, 2025-$0.15-$0.10-$0.11 - -$0.09-52.90%MissN/A30 up, 2 downJan 6, 2026$79.43M
    Aug 31, 2025-$0.10-$0.12-$0.14 - -$0.09+16.67%BeatN/A40 up, 2 downOct 2, 2025$75.71M
    May 31, 2025-$0.03-$0.12-$0.17 - -$0.09+75.00%BeatN/A31 up, 1 downJul 15, 2025$80.16M
    Feb 28, 2025$0.03-$0.13-$0.14 - -$0.11+123.08%BeatN/A30 up, 1 downApr 2, 2025$72.00M
    Nov 30, 2024-$0.04-$0.11-$0.12 - -$0.10+63.64%BeatN/A30 up, 2 downJan 8, 2025$72.84M
    Aug 31, 2024-$0.11-$0.15-$0.16 - -$0.13+26.67%BeatN/A30 up, 0 downOct 3, 2024$67.49M
    May 31, 2024-$0.06-$0.17-$0.21 - -$0.12+64.71%Beat-400.0%30 up, 0 downJul 16, 2024$70.98M
    Feb 29, 2024-$0.16-$0.15-$0.18 - -$0.11-6.67%MissN/A41 up, 0 downApr 4, 2024$75.18M
    Nov 30, 2023-$0.05-$0.07-$0.10 - -$0.06+28.57%Beat-600.0%40 up, 0 downJan 5, 2024$79.07M
    Aug 31, 2023-$0.12-$0.13-$0.15 - -$0.11+7.69%BeatN/A40 up, 0 downOct 4, 2023$78.68M
    May 31, 2023$0.02$0.02$0.01 - $0.030.00%In line+100.0%40 up, 0 downJul 12, 2023$91.07M
    Feb 28, 2023-$0.03-$0.01-$0.02 - $0.00-200.00%Miss-200.0%40 up, 0 downMar 30, 2023$80.71M
    Nov 30, 2022$0.01-$0.01-$0.02 - $0.00+200.00%BeatN/A40 up, 0 downJan 5, 2023$85.43M
    Aug 31, 2022-$0.06-$0.02-$0.03 - -$0.01-200.00%MissN/A40 up, 0 downOct 6, 2022$81.54M
    May 31, 2022$0.01$0.01$0.00 - $0.010.00%In lineN/A40 up, 0 downJul 12, 2022$87.00M
    Feb 28, 2022$0.03-$0.01-$0.03 - $0.00+400.00%Beat+50.0%40 up, 0 downApr 7, 2022$73.97M
    Nov 30, 2021-$0.02$0.01$0.00 - $0.01-300.00%Miss-300.0%40 up, 0 downJan 6, 2022$78.28M
    Aug 31, 2021-$0.02-$0.04-$0.06 - -$0.03+50.00%Beat-200.0%4N/ASep 30, 2021$76.97M
    May 31, 2021-$0.51$0.00-$0.01 - $0.00N/AN/AN/A3N/AJul 13, 2021$76.84M
    Feb 28, 2021$0.02-$0.02-$0.04 - -$0.01+200.00%Beat+100.0%3N/AMar 30, 2021$71.18M
    Nov 30, 2020$0.01-$0.02-$0.03 - -$0.01+150.00%Beat-83.3%3N/AJan 7, 2021$72.77M
    Aug 31, 2020$0.02-$0.07-$0.08 - -$0.05+128.57%Beat-75.0%3N/ASep 29, 2020$70.22M
    May 31, 2020-$0.06-$0.06-$0.09 - $0.000.00%In line-124.0%3N/AJul 16, 2020$58.33M
    Feb 29, 2020$0.01-$0.03-$0.03 - -$0.03+133.33%Beat-94.7%3N/AApr 7, 2020$69.78M
    Nov 30, 2019$0.06$0.02$0.01 - $0.04+200.00%Beat-72.7%3N/AJan 7, 2020$70.00M
    Aug 31, 2019$0.08$0.04$0.04 - $0.05+100.00%Beat-50.0%4N/AOct 3, 2019$66.04M
    May 31, 2019$0.25$0.26$0.25 - $0.26-3.85%Miss+25.0%4N/AJul 10, 2019$71.18M
    Feb 28, 2019$0.19$0.22$0.20 - $0.22-13.64%Miss-24.0%4N/AApr 2, 2019$65.52M
    Nov 30, 2018$0.22$0.21$0.20 - $0.22+4.76%Beat+37.5%4N/AJan 4, 2019$69.98M
    Aug 31, 2018$0.16$0.18$0.16 - $0.19-11.11%Miss+33.3%4N/ASep 27, 2018$63.94M
    May 31, 2018$0.20$0.21$0.20 - $0.21-4.76%Miss+5.3%4N/AJul 11, 2018$5.69M
    Feb 28, 2018$0.25$0.19$0.17 - $0.20+31.58%Beat+31.6%5N/AMar 29, 2018$83.85M
    Nov 30, 2017$0.16$0.16$0.15 - $0.170.00%In line-15.8%5N/AJan 4, 2018$86.71M
    Aug 31, 2017$0.12$0.16$0.14 - $0.18-25.00%Miss-29.4%5N/ASep 28, 2017$85.41M
    May 31, 2017$0.19$0.16$0.15 - $0.18+18.75%Beat0.0%5N/AJul 18, 2017$7.06M
    Feb 28, 2017$0.19$0.15N/A+26.67%Beat+26.7%N/AN/AMar 30, 2017$85.60M
    Nov 30, 2016$0.19$0.16N/A+18.75%Beat+35.7%N/AN/AJan 6, 2017$89.03M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended May 31, 2026 was -$0.30, after -$0.15 the year before. It was $0.74 for the year ended May 31, 2017, the oldest of the 9 fiscal years below with reported EPS.

    Fiscal year endedEPSChange
    May 31, 2026-$0.30N/A
    May 31, 2025-$0.15N/A
    May 31, 2024-$0.39N/A
    May 31, 2023-$0.06N/A
    May 31, 2022Not reportedN/A
    May 31, 2021-$0.46-605.9%
    May 31, 2020$0.09-89.0%
    May 31, 2019$0.82+12.3%
    May 31, 2018$0.73N/A
    May 31, 2017$0.74N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,6876
    2026Q2Jun 30, 20265,5736
    2026Q1Mar 31, 20262,8786
    2025Q4Dec 31, 20256,4936
    2025Q3Sep 30, 20255,5686
    2025Q2Jun 30, 20257,2606
    2025Q1Mar 31, 20256,2846
    2024Q4Dec 31, 20247,0537

    2026Q3 Earnings Call

    Opening remarks

    James Clemmer President & Chief Executive Officer Thank you, operator. Good morning, everyone, and thank you for joining us for AngioDynamics' Fiscal 2026 Third Quarter Earnings Call. Joining me on today's call is Steve Trowbridge, AngioDynamics' Executive Vice President and Chief Financial Officer. Our third quarter was strong across the board, and I am proud of how our team continues to execute. We maintained our trend of driving top line growth, led by impressive growth in our Med Tech segment. Beyond the top line, we continued to deliver strong profitability by expanding our adjusted EBITDA. Our performance continues to show that our strategy to drive profitable growth in our high-margin, large Med Tech markets is working. Based on that, we are once again raising our full year guidance for net sales and adjusted EBITDA. That is our third consecutive quarter of raised guidance, and Steve will touch upon the details shortly. I am very proud of the resilience we have built into the business. We've developed this company around cardiovascular and oncology markets with three product portfolios that we are really excited about. Along the way, we've had to work through a manufacturing transition, deal with tariffs and manage through a lot of macro uncertainty. None of that has slowed us down. That is because we have great people who know how to get the job done and the results we are putting up are not because one thing went right; it is years of work coming together. Within our Med Tech business, Auryon continued its strong momentum with the nineteenth consecutive quarter of double-digit year-over-year growth, which is a track record we are very proud of. We have consistently driven revenue growth by leveraging our superior technology to take share and our push into the hospital market keeps paying off, driving both top line growth and better economics. And it is not just about taking share. With our AMBITION BTK study, we are not only winning in the current market, we are working to make the market larger. Internationally, we are seeing continued traction following our CE Mark approval. Turning to our Mechanical Thrombectomy business. We loved what we saw this quarter. Our combined portfolio of AlphaVac and AngioVac grew approximately 18% over the prior year, demonstrating the superior clinical performance of this portfolio. AlphaVac in particular had an outstanding quarter, delivering strong year-over-year growth and driving the largest sequential revenue increase we have seen since its launch. New accounts are coming on, more hospitals are bringing us through the VAC process and into inventory. And utilization within existing accounts keeps increasing. The physician feedback on this product is consistently strong.

    Frequently Asked Questions About ANGO

    When is AngioDynamics's next earnings date?

    AngioDynamics's next earnings report is expected for Jan 4, 2027.

    Did ANGO beat earnings estimates last quarter?

    Yes. AngioDynamics reported EPS of -$0.04 for the quarter ended Aug 31, 2026, above the -$0.10 estimate, a 60.00% surprise.

    What EPS do analysts expect from ANGO next quarter?

    The consensus EPS estimate for AngioDynamics for the quarter ending Nov 30, 2026 is -$0.07 from 3 analysts, with estimates from -$0.11 to -$0.02.

    How often does ANGO beat earnings estimates?

    AngioDynamics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +55.00%.